CYCLERION THERAPEUTICS INC (CYCN) Stock Overview
USA - NASDAQ:CYCN - US23255M2044 - Common Stock
CYCN Key Statistics, Chart & Performance
The current stock price of CYCN is 1.97 USD. In the past month the price decreased by -11.3%. In the past year, price decreased by -30.85%.
CYCN Latest News, Press Relases and Analysis
CYCN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.26 | 397.72B | ||
| AMGN | AMGEN INC | 13.38 | 157.08B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 89.25 | 50.61B | ||
| INSM | INSMED INC | N/A | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.58B | ||
| NTRA | NATERA INC | N/A | 26.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.24 | 21.68B |
Related stock screener links
About CYCN
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Company Info
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Phone: 16176217722
CYCLERION THERAPEUTICS INC / CYCN FAQ
What does CYCLERION THERAPEUTICS INC do?
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
What is the current price of CYCN stock?
The current stock price of CYCN is 1.97 USD. The price decreased by -3.43% in the last trading session.
Does CYCLERION THERAPEUTICS INC pay dividends?
CYCN does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYCN stock?
CYCN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy CYCN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CYCN.
What is the employee count for CYCN stock?
CYCLERION THERAPEUTICS INC (CYCN) currently has 1 employees.
CYCN Technical Analysis
CYCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYCN. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability.
CYCN Financial Highlights
Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 46.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.77% | ||
| ROE | -22.71% | ||
| Debt/Equity | 0 |